The trial met its primary endpoint with a significantly larger proportion of delgocitnib-treated patients achieving treatment success. Delgocitinib cream significantly improved chronic hand eczema in ...

DELTA 3 enrolled 560 delgocitinib-treated completers from DELTA 1/2; 472 were week-52 completers after 16 weeks BID induction ...

Environmental triggers were reported by 69.4% of patients, most commonly water/handwashing, chemical irritants, contact ...

Please provide your email address to receive an email when new articles are posted on . Between 11% and 20% of the population has chronic hand eczema. Respondents used an average of 1.7 prescriptions.

Topical delgocitinib, a pan-Janus kinase inhibitor, was well tolerated and reduced the severity and symptoms of disease in patients with moderate to severe chronic hand eczema, in two phase 3 trials.

Delgocitinib cream was shown to be effective and well-tolerated in adolescents with chronic hand eczema in the phase 3 DELTA TEEN clinical trial.

A first-in-class topical pan-Janus kinase (JAK) inhibitor significantly improved symptoms of moderate to severe chronic hand eczema in two randomized phase III trials. At week 16, more patients ...

Treatment options for severe chronic hand eczema are limited and carry troublesome adverse effects. Delgocitinib cream had superior efficacy compared with oral alitretinoin for this patient population ...

San Diego — Data from an open-label extension study of delgocitinib cream reflects the positive phase 3 safety and efficacy results released > 1 year ago from two separate trials in patients with ...

"Chronic Hand Eczema Market"Key players in the Chronic Hand Eczema market include Basilea Pharmaceutica, Stiefel Laboratories, LEO Pharma, Asana Biosciences, and Incyte Corporation, among others.

(MENAFN- GetNews) (Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Chronic Hand Eczema pipeline constitutes 5+ key companies continuously working towards developing 5+ ...

Please provide your email address to receive an email when new articles are posted on . Adults with atopic dermatitis with hand involvement saw skin improvements as early as 2 weeks with tralokinumab.